Dongin (Donoven) Kim, Ph.D.
Assistant Professor
Pharmaceutical Sciences
Phone (405) 271-6593 x 47473
Office College of Pharmacy, CPB 317
Email dongin-kim@ouhsc.edu
Publications & Presentations
- 11. Kim D. Intraocular RGD-Engineered exosomes and active targeting of choroidal neovascularization (CNV). Cells/MDPI. 2022; 11 : 2573
12. Kim D. A Benzenesulfonamide-based mitochondrial uncoupler induces endoplasmic reticulum stress and immunogenic cell death in epithelial ovarian cancer . Molecular Cancer Theraeputics. 2021; 21 : 2398-2409
13. Kim D. A Kidney-Targeted Nanoparticle to Augment Renal Lymphatic Density Decreases Blood Pressure in Hypertensive Mice . Pharmaceutics. 2021; 14 : 84
14. Kim D. pH-responsive Nanomedicine for Image-guided Drug Delivery . Pan Stanford Publishing. 2021
15. Kim D. Metabolic and immunomodulatory control of type 1 diabetes via orally delivered bile-acid-polymer nanocarriers of insulin or rapamycin. Nature Biomedical Engineering. In Press; 5 : 983-997
Grants
- 1. Extracellular Vesicle-Based Intraocular Therapy Combined with Active Targeting of Ocular Neovascularization. NEI. Start Date: 2024. End Date: 2029.
2. MiPEP133, a New Tumor Suppressor for Ovarian Cancer. American Cancer Society. Start Date: 2024. End Date: 2027.
3. Extracellular Vesicle Therapy for Diabetic Retinopathy. NEI. Start Date: 2023. End Date: 2024.
4. Lymphatics and lymphangiogenesis in kidney function and inflammation. NIH. Start Date: 2019. End Date: 2024.
5. Extracellular Vesicle Therapy for Diabetic Retinopathy. NEI. Start Date: 2023. End Date: 2024.
Awards and Honors
no results
Education
- 1. Degree: Ph D. University of Utah. Date: 2009.
2. Degree: MS. University of Florida. Date: 2002.
3. Degree: BS. Ajou University. Date: 1999.
Administrative Assignments
no results